

LISTING OF CLAIMS:

Below is a listing of the claims present in this application.

1. (Cancelled) A composition for promoting passive extension of bladder smooth muscle, comprising adrenomedullin.
2. (Cancelled) A composition according to claim 1, used to ameliorate a urination disorder.
3. (Cancelled) A composition according to claim 2, wherein the urination disorder is a urinary incontinence selected from the group consisting of urge incontinence, reflex incontinence, and overflow incontinence.
4. (Cancelled) A composition according to claim 1, wherein the adrenomedullin is:
 - (a) a peptide comprising an amino acid sequence from Ser in position 13 to Tyr in position 52 of SEQ ID NO: 1 in SEQUENCE LISTING;
 - (b) a peptide comprising an amino acid sequence having one or several amino acid deleted, substituted, or added in the amino acid sequence (a), and having an action of promoting extension of bladder smooth muscle.
5. (Cancelled) A composition according to claim 4, wherein the adrenomedullin is:
 - (c) a peptide comprising an amino acid sequence from Tyr in position 1 to Tyr in position 52 of SEQ ID NO: 2 in SEQUENCE LISTING; or
 - (d) a peptide comprising an amino acid sequence having one or several amino acid deleted, substituted, or added in the amino acid sequence (c), and having an action of promoting extension of bladder smooth muscle.

6. (Cancelled) A composition according to claim 5, wherein the adrenomedullin is:

(e) a peptide comprising an amino acid sequence from Ala in position -73 to Tyr in position 52 of SEQ ID NO: 2 in SEQUENCE LISTING; or

(f) a peptide comprising an amino acid sequence having one or several amino acid deleted, substituted, or added in the amino acid sequence (e), and having an action of promoting extension of bladder smooth muscle.

7. (Cancelled) A composition according to claim 6, wherein the adrenomedullin is:

(g) a peptide comprising an amino acid sequence from Met in position -94 to Leu in position 91 of SEQ ID NO: 2 in SEQUENCE LISTING; or

(h) a peptide comprising an amino acid sequence having one or several amino acid deleted, substituted, or added in the amino acid sequence (g), and having an action of promoting extension of bladder smooth muscle.

8. (Cancelled) A composition according to any of claims 1 and 4 to 7, wherein the C-terminus of the adrenomedullin is amidated.

9. (Cancelled) A composition according to any of claims 1 and 4 to 7, wherein Gly is added to the C-terminus of the adrenomedullin.

10. (Cancelled) A composition according to any of claims 1 and 4 to 7, wherein in the adrenomedullin, Cys in position 16 and Cys in position 21 of SEQ ID NO: 2 in SEQUENCE LISTING are crosslinked.

11. (Cancelled) A composition according to claim 10, wherein the crosslink is a disulfide bond.

12. (Cancelled) A composition according to claim 10, wherein the crosslink is a $-\text{CH}_2-\text{CH}_2-$ bond.

13. (Previously Amended) A method for ameliorating a urination disorder comprising administering a composition comprising adrenomedullin.

14. (Cancelled) Use of adrenomedullin in production of a drug for ameliorating a urination disorder.

15. (Previously Added) A method according to claim 13, wherein the urination disorder is a urinary incontinence selected from the group consisting of urge incontinence, reflex incontinence, and overflow incontinence.

16. (Previously Added) A method according to claim 13, wherein the adrenomedullin is:

(a) a peptide comprising an amino acid sequence from Ser in position 13 to Tyr in position 52 of SEQ ID NO: 2 in SEQUENCE LISTING; or

(b) a peptide comprising an amino acid sequence having at least about 80% homology with the amino acid sequence (a), and having an action of promoting extension of bladder smooth muscle.

17. (Previously Added) A method according to claim 13, wherein the adrenomedullin is:

(a) a peptide comprising an amino acid sequence from Tyr in position 1 to Tyr in position 52 of SEQ IS NO: 2 in SEQUENCE LISTING; or

(b) a peptide comprising an amino acid sequence having at least about 80% homology with the amino acid sequence (a), and having an action of promoting extension of bladder smooth muscle.

18. (Previously Added) A method according to claim 13, wherein the adrenomedullin is:

(a) a peptide comprising an amino acid sequence from Ala in position -73 to Tyr in position 52 of SEQ ID NO: 2 in SEQUENCE LISTING; or

(b) a peptide comprising an amino acid sequence having at least about 80% homology with the amino acid sequence (a), and having an action of promoting extension of bladder smooth muscle.

19. (Previously Added) A method according to claim 13, wherein the adrenomedullin is:

(a) a peptide comprising an amino acid sequence from Met in position -94 to Leu in position 91 of SEQ IS NO: 2 in SEQUENCE LISTING; or

(b) a peptide comprising an amino acid sequence having at least about 80% homology with the amino acid sequence (a), and having an action of promoting extension of bladder smooth muscle.

20. (Previously Added) A method according to claim 13, wherein the C-terminus of the adrenomedullin is amidated.

21. (Previously Added) A method according to claim 13, wherein Gly is added to the C-terminus of the adrenomedullin.

22. (Previously Added) A method according to claim 13, wherein in the adrenomedullin, Cys in position 16 and Cys in position 21 of SEQ ID NO: 2 in SEQUENCE LISTING are crosslinked.

23. (Previously Added) A method according to claim 22, wherein the crosslink is a disulfide bond.

24. (Previously Added) A method according to claim 22, wherein the crosslink is a $-\text{CH}_2-\text{CH}_2-$ bond.

25. (Previously Added) A method for promoting passive extension of bladder smooth muscle comprising administering a composition comprising adrenomedullin.

26. (Previously Added) A method according to claim 25, wherein the adrenomedullin is:

(a) a peptide comprising an amino acid sequence from Ser in position 13 to Tyr in position 52 of SEQ ID NO: 2 in SEQUENCE LISTING; or

(b) a peptide comprising an amino acid sequence having at least about 80% homology with the amino acid sequence (a), and having an action of promoting extension of bladder smooth muscle.

27. (Previously Added) A method according to claim 25, wherein the adrenomedullin is:

- (a) a peptide comprising an amino acid sequence from Tyr in position 1 to Tyr in position 52 of SEQ ID NO: 2 in SEQUENCE LISTING; or
- (b) a peptide comprising an amino acid sequence having at least about 80% homology with the amino acid sequence (a), and having an action of promoting extension of bladder smooth muscle.

28. (Previously Added) A method according to claim 25, wherein the adrenomedullin is:

- (a) a peptide comprising an amino acid sequence from Ala in position -73 to Tyr in position 52 of SEQ ID NO: 2 in SEQUENCE LISTING; or
- (b) a peptide comprising an amino acid sequence having at least about 80% homology with the amino acid sequence (a), and having an action of promoting extension of bladder smooth muscle.

29. (Previously Added) A method according to claim 25, wherein the adrenomedullin is:

- (a) a peptide comprising an amino acid sequence from Met in position -94 to Leu in position 91 of SEQ ID NO: 2 in SEQUENCE LISTING; or
- (b) a peptide comprising an amino acid sequence having at least about 80% homology with the amino acid sequence (a), and having an action of promoting extension of bladder smooth muscle.

30. (Previously Added) A method according to claim 25, wherein the C-terminus of the adrenomedullin is amidated.

31. (Previously Added) A method according to claim 25, wherein Gly is added to the C-terminus of the adrenomedullin.

32. (Previously Added) A method according to claim 25, wherein in the adrenomedullin, Cys in position 16 and Cys in position 21 of SEQ ID NO: 2 in SEQUENCE LISTING are crosslinked.

33. (Previously Added) A method according to claim 32, wherein the crosslink is a disulfide bond.

34. (Previously Added) A method according to claim 32, wherein the crosslink is a $-\text{CH}_2-\text{CH}_2-$ bond.